Advertisement




Related Videos

Deborah Collyar: What's In It for Patients?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement



Advertisement